Koch, Jan-Christoph

[["dc.bibliographiccitation.artnumber","293"],["dc.bibliographiccitation.journal","Frontiers in Neurology"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Lingor, Paul"],["dc.contributor.author","Weber, Markus"],["dc.contributor.author","Camu, William"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Hilgers, Reinhard"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Neuwirth, Christoph"],["dc.contributor.author","Günther, René"],["dc.contributor.author","Benatar, Michael"],["dc.contributor.author","Kuzma-Kozakiewicz, Magdalena"],["dc.contributor.author","Bidner, Helen"],["dc.contributor.author","Blankenstein, Christiane"],["dc.contributor.author","Frontini, Roberto"],["dc.contributor.author","Ludolph, Albert"],["dc.contributor.author","Koch, Jan C."],["dc.date.accessioned","2019-07-09T11:51:01Z"],["dc.date.available","2019-07-09T11:51:01Z"],["dc.date.issued","2019"],["dc.description.abstract","Objectives: Disease-modifying therapies for amyotrophic lateral sclerosis (ALS) are still not satisfactory. The Rho kinase (ROCK) inhibitor fasudil has demonstrated beneficial effects in cell culture and animal models of ALS. For many years, fasudil has been approved in Japan for the treatment of vasospasm in patients with subarachnoid hemorrhage with a favorable safety profile. Here we describe a clinical trial protocol to repurpose fasudil as a disease-modifying therapy for ALS patients. Methods: ROCK-ALS is a multicenter, double-blind, randomized, placebo-controlled phase IIa trial of fasudil in ALS patients (EudraCT: 2017-003676-31, NCT: 03792490). Safety and tolerability are the primary endpoints. Efficacy is a secondary endpoint and will be assessed by the change in ALSFRS-R, ALSAQ-5, slow vital capacity (SVC), ECAS, and the motor unit number index (MUNIX), as well as survival. Efficacy measures will be assessed before (baseline) and immediately after the infusion therapy as well as on days 90 and 180. Patients will receive a daily dose of either 30 or 60 mg fasudil, or placebo in two intravenous applications for a total of 20 days. Regular assessments of safety will be performed throughout the treatment period, and in the follow-up period until day 180. Additionally, we will collect biological fluids to assess target engagement and evaluate potential biomarkers for disease progression. A total of 120 patients with probable or definite ALS (revised El Escorial criteria) and within 6-18 months of the onset of weakness shall be included in 16 centers in Germany, Switzerland and France. Results and conclusions: The ROCK-ALS trial is a phase IIa trial to evaluate the ROCK-inhibitor fasudil in early-stage ALS-patients that started patient recruitment in 2019."],["dc.identifier.doi","10.3389/fneur.2019.00293"],["dc.identifier.pmid","30972018"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16031"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59859"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Clinical and Translational Neuroscience"],["dc.bibliographiccitation.lastpage","5"],["dc.bibliographiccitation.volume","4"],["dc.contributor.author","Müller, Sebastian J."],["dc.contributor.author","Khadhraoui, Eya"],["dc.contributor.author","Allam, Ibrahim"],["dc.contributor.author","Argyriou, Loukas"],["dc.contributor.author","Hehr, Ute"],["dc.contributor.author","Liman, Jan"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Bähr, Mathias"],["dc.contributor.author","Riedel, Christian H."],["dc.contributor.author","Koch, Jan C."],["dc.date.accessioned","2020-05-28T12:53:29Z"],["dc.date.accessioned","2021-10-27T13:22:13Z"],["dc.date.available","2020-05-28T12:53:29Z"],["dc.date.available","2021-10-27T13:22:13Z"],["dc.date.issued","2020"],["dc.description.abstract","Cerebral Autosomal Recessive Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CARASIL, Maedasyndrome) is an extremely rare autosomal-recessive genetic disorder with a serious arteriopathy causing subcorticalinfarcts and leukoencephalopathy. In less than 20 cases, a genetic mutation was proven. Patients suffer from alopecia, discherniations, and spondylosis. Between the age of 30 and 40, the patients typically develop severe cerebral infarcts. Clinicalsymptoms, genetic study, magnetic resonance imaging (MRI), and coronary angiography of a patient with proven CARASILare presented. The patient showed the typical phenotype with cerebral small-vessel disease, cerebral infarcts, spondylosis,and abnormal hair loss. Additionally, distinct cerebral microhemorrhage and a severe coronary artery disease (CAD)were found, which have not been reported before for CARASIL. Mutation screening revealed the presence of ahomozygous c.1022G > T substitution in the HTRA1 gene. Evidence from other publications supports a pathogenetic linkbetween the HTRA1 mutation and CAD as a new feature of CARASIL. This is the first report about CARASIL with aconcomitant severe CAD. Thus, in patients with CARASIL, other vessel diseases should also be considered."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2020"],["dc.identifier.doi","10.1177/2514183X20914182"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17348"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/92075"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.relation.eissn","2514-183X"],["dc.relation.issn","2514-183X"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","CARASIL with coronary artery disease and distinct cerebral microhemorrhage: A case report and literature review"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","101639"],["dc.bibliographiccitation.journal","NeuroImage Clinical"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Maier, Ilko L."],["dc.contributor.author","Hofer, Sabine"],["dc.contributor.author","Joseph, Arun A."],["dc.contributor.author","Merboldt, K.-Dietmar"],["dc.contributor.author","Eggert, Eva"],["dc.contributor.author","Behme, Daniel"],["dc.contributor.author","Schregel, Katharina"],["dc.contributor.author","Brelie, Christian von der"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Koch, Jan-Christoph"],["dc.contributor.author","Psychogios, Marios-Nikos"],["dc.contributor.author","Frahm, Jens"],["dc.contributor.author","Liman, Jan"],["dc.contributor.author","Bähr, Mathias"],["dc.date.accessioned","2019-07-09T11:50:09Z"],["dc.date.available","2019-07-09T11:50:09Z"],["dc.date.issued","2019"],["dc.description.abstract","BACKGROUND: Degenerative changes of the cervical spinal column are the most common cause of spinal cord lesions in the elderly. Conventional clinical, electrophysiological and radiological diagnostics of spinal cord compression are often inconsistent. MATERIALS AND METHODS: The feasibility and diagnostic potential of a novel T1 mapping method at 0.5 mm resolution and 4 s acquisition time was evaluated in 14 patients with degenerative cervical spinal canal stenosis (SCS) and 6 healthy controls. T1 mapping was performed in axial sections of the stenosis as well as above and below. All subjects received standard T2-weighted MRI of the cervical spine (including SCS-grading 0-III), electrophysiological and clinical examinations. RESULTS: Patients revealed significantly decreased T1 relaxation times of the compressed spinal cord within the SCS (912 ± 53 ms, mean ± standard deviation) in comparison to unaffected segments above (1027 ± 39 ms, p < .001) and below (1056 ± 93 ms, p < .001). There was no difference in mean T1 in unaffected segments in patients (p = .712) or between segments in controls (p = .443). Moreover, T1 values were significantly lower in grade II (881 ± 46 ms, p = .005) than in grade I SCS (954 ± 29 ms). Patients with central conduction deficit tended to have lower T1 values within the SCS than patients without (909 ± 50 ms vs 968 ± 7 ms, p = .069). CONCLUSION: Rapid high-resolution T1 mapping is a robust MRI method for quantifying spinal cord compression in patients with cervical SCS. It promises additional diagnostic insights and warrants more extended patient studies."],["dc.identifier.doi","10.1016/j.nicl.2018.101639"],["dc.identifier.pmid","30553763"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15872"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59713"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2213-1582"],["dc.rights","CC BY-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nd/4.0"],["dc.subject.ddc","610"],["dc.title","Quantification of spinal cord compression using T1 mapping in patients with cervical spinal canal stenosis - Preliminary experience"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]